{
  "docId": "019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "docSlug": "5bc6ecf6756c39ce2bfe560c6ffb0fc7",
  "documentTitle": "ATAI | Investor Presentation Deck | 31 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 31,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "key_takeaways",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The chart displays HCQ-29 subscale scores over time (Pre-dose, Discharge, 1 Month) for four dimensions of craving.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e8f5-748b-98ae-3f4a3c3c68f5/19",
  "deckHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5",
  "deckJsonHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5.json",
  "deckAnchorHref": "/decks/019de075-e8f5-748b-98ae-3f4a3c3c68f5#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Self-reported dimensions of craving",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c71416f3-66ba-4e4e-bb65-5257aec78c72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "list",
      "text": "1. Summary: A single-dose of ibogaine showed reductions in self-reported opioid cravings in 74 opioid dependent patients. 2. Efficacy - Relapse Prevention (shown left): Opioid dependent patients had significant reductions in the mean scores of four HCQ-29 domains of craving measured at program discharge and out to 1 month for patients continuing through study completion. Cravings are an important mediator of relapse. 3. Efficacy - Post-Acute Withdrawal Syndrome: signs and symptoms at post dose assessments were reduced compared to pre-dose baseline withdrawal severity measures. Objective signs of opioid withdrawal were mild and none were exacerbated at later time points. 4. Safety: Ibogaine was reported to be well tolerated with no serious adverse events.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e57e6932-82bb-4ff5-8168-34b0a4e4ba4a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.03,
        "y": 0.1
      },
      "kind": "paragraph",
      "text": "Results from an open-label study of 8-12 mg/kg of ibogaine in patients seeking detoxification from opioids and cocaine",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c419e0b-a79a-4b54-b37c-01e3d9de2883",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1 Mash et al., “Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes” (2018)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11d64d0c-6ac9-48ce-bc36-a070db570a66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Clinical Evidence: Efficacy of ibogaine in Open-Label Safety and Efficacy Study",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30e22e41-ec3e-4a76-8bf5-afe3d1887246",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 6,
      "beatId": "3567efa9-5c4b-4d3c-88d1-7a53a3a212bc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The presentation showcases the progress and achievements of atai Life Sciences' drug development programs, including efficacy and safety data.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 6,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "70da09d2-e8b7-478f-a3d9-ef5654b6b7c9",
      "evidence": "The presentation presents data and results from clinical trials, demonstrating the potential for atai Life Sciences' treatments to become first and best-in-class.",
      "position": 1,
      "objective": "Showcase the potential for first and best-in-class treatments",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}